Back

COVID-19 rebound after Paxlovid and Molnupiravir during January-June 2022

2022-06-22 infectious diseases Title + abstract only
View on medRxiv
Show abstract

ImportanceRecent case reports document that some patients who were treated with Paxlovid experienced rebound COVID-19 infections and symptoms 2 to 8 days after completing a 5-day course of Paxlovid. The Centers for Disease Control and Prevention (CDC) has recently issued a Health Alert Network Health Advisory to update the public on the potential for COVID-19 rebound after Paxlovid treatments. However, the rates of COVID-19 rebound in a real-world population or whether rebound is unique to Paxlo...

Predicted journal destinations

1
Clinical Infectious Diseases
219 training papers
Top 0.6% 16.4%
2
PLOS ONE
1737 training papers
Top 69% 7.2%
3
JAMA Network Open
125 training papers
Top 0.6% 7.2%
4
Open Forum Infectious Diseases
124 training papers
Top 0.8% 5.9%
5
Infectious Diseases and Therapy
18 training papers
#1 3.6%
6
International Journal of Infectious Diseases
115 training papers
Top 4% 3.6%
7
Nature Communications
483 training papers
Top 30% 3.6%
8
Scientific Reports
701 training papers
Top 70% 3.6%
9
BMJ Open
553 training papers
Top 44% 2.6%
10
Vaccine
140 training papers
Top 5% 1.8%
11
BMJ
49 training papers
Top 2% 1.8%
12
New England Journal of Medicine
49 training papers
Top 1% 1.8%
13
BMC Infectious Diseases
110 training papers
Top 9% 1.8%
14
Nature Medicine
88 training papers
Top 4% 1.8%
15
The Journal of Infectious Diseases
137 training papers
Top 8% 1.8%
16
BMC Medicine
155 training papers
Top 19% 1.4%
17
Clinical Microbiology and Infection
54 training papers
Top 4% 1.4%
18
Frontiers in Medicine
99 training papers
Top 12% 1.4%
19
Vaccines
131 training papers
Top 8% 1.2%
20
Journal of Medical Virology
95 training papers
Top 10% 1.1%
21
Frontiers in Pharmacology
27 training papers
Top 2% 1.1%
22
PLOS Medicine
95 training papers
Top 15% 1.1%
23
Antimicrobial Agents and Chemotherapy
17 training papers
Top 0.5% 1.1%
24
Annals of Internal Medicine
27 training papers
Top 0.8% 0.9%
25
The Lancet Infectious Diseases
57 training papers
Top 7% 0.9%
26
Emerging Microbes & Infections
20 training papers
Top 0.7% 0.9%
27
Emerging Infectious Diseases
84 training papers
Top 15% 0.9%
28
Medicine
29 training papers
Top 5% 0.9%
29
eLife
262 training papers
Top 59% 0.7%
30
Eurosurveillance
77 training papers
Top 16% 0.7%